



Abstract 1548

PROPEL: A phase 1/2 trial of bempegaldesleukin (BEMPEG; NKTR-214) plus pembrolizumab in lung cancer and other advanced solid tumours

D.R. Spigel, et al.

Sarah Cannon Research Institute, TN, USA

Bempegaldesleukin, in combination with pembrolizumab, is an investigational combination therapy and is not currently approved by the US FDA or other regulatory authorities

D.R. Spigel, Sarah Cannon Research Institute, USA

JANUARY 28-31, 2021 | WORLDWIDE VIRTUAL EVENT



wclc2020.IASLC.com | #WCLC20 CONQUERING THORACIC CANCERS WORLDWIDE

Full list of authors

D.R. Spigel^{1*}, D. Rodríguez-Abreu², F. Cappuzzo³, V. Velcheti⁴, A.K. Ganti⁵, D. Johnson⁶, R. Govindan⁷, S. Antonia⁸, B. Besse⁹, M. Altan¹⁰, M. Edelman¹¹, S. Ramalingam¹², E. Felip¹³, S.M. Gadgeel¹⁴, O. Juan-Vidal¹⁵, A. Gupta¹⁶, S. Currie¹⁶, W. Lin¹⁶, M. Tagliaferri¹⁶, M. Reck¹⁷

 ¹Sarah Cannon Research Institute, Nashville/United States of America, ²Hospital Universitario Insular de Gran Canaria, Gran Canaria/Spain, ³Istituto Nazionale Tumori "Regina Elena", Rome, Italy, ⁴Perlmutter Cancer Center NYU Langone, New York/United States of America, ⁵University of Nebraska Medical Center, VA Nebraska Western Iowa Health Care System, Omaha/United States of America, ⁶Ochsner Medical Center, New Orleans/United States of America, ⁷Washington University School of Medicine, St. Louis/United States of America, ⁸Duke Cancer Institute, Duke University, Durham/United States of America, ⁹Institut Gustave Roussy, Villejuif/France,
 ¹⁰The University of Texas MD Anderson Cancer Center, Houston/United States of America, ¹¹Fox Chase Cancer Center, Philadelphia/United States of America, ¹²Winship Cancer Institute, Emory University, Atlanta/United State of America, ¹³Vall d'Hebron University Hospital, Barcelona/Spain, ¹⁴Henry Ford Hospital, Detroit/United States of America, ¹⁵Hospital Universitari i Politècnic La Fe, Valencia/Spain, ¹⁶Nektar Therapeutics, San Francisco/United States of America, ¹⁷Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf/Germany



wclc2020.IASLC.com | #WCLC20

Background: CPIs and Unmet Need in Advanced NSCLC

- CPIs have become a standard treatment for many cancers, including advanced NSCLC¹
- However, they have shown limited efficacy as a single agent in patients with low or no (negative) PD-L1 expression²

There is an unmet need for novel immunotherapy agents for patients who are unlikely to respond to CPI (with low or negative PD-L1 expression) and to provide deeper, prolonged responses in those who do respond

1L, first line; CPI, checkpoint inhibitor; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1.

1. NCCN Clinical Practice Guidelines in Oncology in NSCLC: version 6.2020; June 15, 2020; 2. Garon EB, et al. N Engl J Med 2015;372:2018–2028.




wclc2020.IASLC.com | #WCLC20

CONQUERING THORACIC CANCERS WORLDWIDE

Background: Bempegaldesleukin

- Bempegaldesleukin (BEMPEG; NKTR-214) is a first-in-class CD122-preferential IL-2 pathway agonist^{1–4}
- It directly activates and expands effector T cells and natural killer cells without increases in immunosuppressive regulatory T cells^{1,2,5}



CD, cluster of differentiation; CPI, checkpoint inhibitor; IL, interleukin; NK, natural killer cell;


- NSCLC, non-small cell lung cancer; PEG, releasable polyethylene glycol; PD-L1, programmed death-ligand 1; Treg, T-regulatory cell.
- 1. Bentebibel SE, et al. Cancer Discov 2019;9:711–721; 2. Sharma M, et al. Nat Commun 2020;11(1):661; 3. Diab A, et al. J Clin Oncol 2018;36(15 suppl):3006;
- 4. Charych DH, et al. PLoS ONE 2017;12(7):e0179431; 5. Charych DH, et al. Clin Cancer Res 2016;22:680-690.



Background: Bempegaldesleukin Plus Nivolumab

- BEMPEG has previously been combined with nivolumab, demonstrating promising efficacy^{1,2}
- This combination has been shown to convert baseline tumours from PD-L1 non-expressing to PD-L1 expressing¹





31 patients were available with matched baseline and week 3 results for PD-L1 status. Of these, 17 were PD-L1 negative at baseline. PD-L1 was assessed on tumour cells using a validated 28-8 method. Example image shown for a patient with urothelial carcinoma at baseline and week 3, 20x magnification.


CR, complete response; NEG, negative; PD, progressive disease; PD-L1, programmed cell death-ligand 1; POS, positive; PR, partial response; SD, stable disease.

1. Diab A, et al. Cancer Discov 2020;10(8):1158-73; 2. Diab A, et al. J Clin Oncol 2018;36(15 suppl):3006.



CONQUERING THORACIC CANCERS WORLDWIDE

PROPEL: Phase 1/2 Study Design



^aPatients will be treated until disease progression, death, unacceptable toxicity, symptomatic deterioration, lost to follow up, investigator or patient decision to discontinue treatment, withdrawal of consent or termination of the study by the sponsor. ^bIn France, patients in subgroup PD-L1 < 1-49% will be excluded.

PD-L1, programmed death-ligand 1; Q3W, every 3 weeks.

ClinicalTrials.gov. NCT03138889. https://clinicaltrials.gov/ct2/show/NCT03138889. Accessed January 7, 2021.



wclc2020.IASLC.com | #WCLC20

CONQUERING THORACIC CANCERS WORLDWIDE

Study Assessments



Safety assessments include adverse events, clinical laboratory tests, vital signs and physical exams



Blood samples for pharmacokinetic analyses from all patients



Systemic and tumour tissue-based pharmacodynamic effects of BEMPEG plus pembrolizumab



Blood samples (plasma and serum) for exploratory biomarker analyses for CVA characterisation at baseline and at the time of a new CVA event



Tumour assessments every 9 weeks ± 7 days from Cycle 1, Day 1



wclc2020.IASLC.com | #WCLC20

CONQUERING THORACIC CANCERS WORLDWIDE

Endpoints

Stage 1: Dose Optimisation (US only) ^a Patients with advanced solid tumours		Stage 2: Dose Expansion (Global) ^a Patients with previously untreated stage IV NSCLC	
Primary endpoints	Secondary endpoints	Primary endpoints	Secondary endpoints
 Safety and tolerability RP2D/MTD Optimal dosing schedule 	 ORR, CBR, DOR, TTR, PFS, OS Assess the association between efficacy measures and PD-L1 expression in tumours 	• ORR	 Safety and tolerability CBR, DOR, TTR, PFS, OS Assess the association between efficacy measures and PD-L1 expression in tumours

^aAll efficacy parameters assessed by RECIST v1.1 expect OS.

CBR, clinical benefit rate; DOR, duration of response; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid tumours; TTR, time to response.RP2D, recommended Phase 2 dose.



wclc2020.IASLC.com | #WCLC20

CONQUERING THORACIC CANCERS WORLDWIDE

Key Eligibility Criteria

- Age ≥18 years
- Measurable disease per RECIST 1.1
- Advanced solid tumours
- ECOG PS of 0 or 1
- Life expectancy >12 weeks
- Patients must not have progressed within 6 months of receiving radiation, surgery, adjuvant, neoadjuvant, or systemic therapy for cancer treatment
- Oxygen saturation \geq 92% on room air for all indications
- Tumour tissue sample: fresh or archival
- Patients with brain metastases are eligible if certain criteria are met

Dose-expansion cohort (NSCLC)

- Histologically or cytologically confirmed diagnosis of stage IV NSCLC
- No known EGFR, ROS1, BRAF v600E or ALK genomic tumour aberrations
- Must not have received prior treatment for metastatic NSCLC or immunotherapy, including IL-2 therapy
- Must undergo a brain MRI at screening

ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; IL, interleukin; MRI, magnetic resonance imaging; NSCLC, non-small cell lung cancer; RECIST, Response Evaluation Criteria in Solid tumours; ROS1, c-ros oncogene 1.



wclc2020.IASLC.com | #WCLC20

CONQUERING THORACIC CANCERS WORLDWIDE

Eligible Tumour Types

Tumour type	Stage	Line of treatment (metastatic setting)	PD-L1 status		
DOSE OPTIMISATION					
Melanoma	Stage III (unresectable) or Stage IV (metastatic)	1 st and 2 nd	Any		
Urothelial carcinoma	Locally advanced or metastatic	1 st and 2 nd	Any		
Head and neck squamous cell carcinoma	Recurrent and unresectable or metastatic	1 st and 2 nd	Any		
Hepatocellular carcinoma	Locally advanced or metastatic	1 st and 2 nd	Any		
Non-small cell lung cancer	Stage IV (metastatic)	1 st and 2 nd	Any		
DOSE EXPANSION					
Non-small cell lung cancer	Stage IV (metastatic)	1 st	Any		

PD-L1, programmed death-ligand 1.



wclc2020.IASLC.com | #WCLC20 CONQUERING THORACIC CANCERS WORLDWIDE

Conclusions: Study Status

- The Phase 1/2 PROPEL study (NCT03138889) evaluates safety and tolerability and assesses the preliminary clinical benefit of the investigational CD122-preferential IL-2 pathway agonist, BEMPEG plus pembrolizumab^{1,2}
- As of December 17, 2020, the PROPEL study has completed its enrollment in the NSCLC Dose Expansion part of the study
 - Expansion of this study and new study arms are planned and will be open to enrollment soon
- The trial is registered with ClinicalTrials.gov, NCT03138889, and the European Clinical Trials Register, 2019-003474-35

NSCLC, non-small cell lung cancer.

^{1.} ClinicalTrials.gov. NCT03138889. https://clinicaltrials.gov/ct2/show/NCT03138889. Accessed January 7, 2021; 2. Charych D, et al. PLoS One 2017;12:e0179431.



wclc2020.IASLC.com | #WCLC20 CONQUERING THORACIC CANCERS WORLDWIDE

Acknowledgements

- We would like to thank all patients, their families and the investigators who are participating in this study
- This study is funded by Nektar Therapeutics, San Francisco, CA. Medical writing assistance was provided by Sara Shaw, PhD CMPP of BOLDSCIENCE Inc., and was funded by Nektar Therapeutics